Preliminary Clinical Experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT Imaging in Prostate Cancer Patients

Table 2

PSA level and PSA doubling time in group of patients with positive and negative FACBC findings.

Studies with positive [^18F]-FACBC findings (I); (𝑛=15^∗)		Studies with negative [^18F]-FACBC findings (II); (𝑛=15^∗)
S-PSA level	S-PSA doubling time**	S-PSA level	S-PSA doubling time**
9.5±16.9 (0.54–69 μg/L)	3.25±2.09 months (0.3–6 months)	1.96±1.87 μg/L (0.11–5.99 μg/L)	31.2±22.02 months (8–84 months)

∗Patient 1 with no cancer was considered negative.
**Statistically significant, 𝑃≤0.0001.